

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

**Draft Minutes  
Controlled Substances Subcommittee  
of the Scientific Advisory Committee  
Electronic Meeting  
October 7, 2024**

**Subcommittee Members Present**

Christopher Bommarito  
Marc A. LeBeau, Ph.D.  
Richard P. Meyers, *Chair*

**Staff Members Present**

David A. Barron, Ph.D., Deputy Director  
Jessica Belton, Forensic Scientist Sr, Controlled Substances Section  
Mason Byrd, Chief Deputy Director  
Linda C. Jackson, Director  
Alka B. Lohmann, Director of Technical Services  
Amanda Pau, Forensic Scientist Sr, Controlled Substances Section  
Farryl Sorokin, PERK Tracking Coordinator  
Elise Stroble, Secretary to the Scientific Advisory Committee  
Rebecca Wagner, Ph.D., Chemistry Research Section Supervisor  
Robyn Weimer, Chemistry Program Manager

**Call to Order by Subcommittee Chair**

Chairman Meyers called the meeting of the Controlled Substances Subcommittee (Subcommittee) to order at 1:16 p.m. He advised the Subcommittee members that, for purposes of a quorum, all members must keep their cameras on, pursuant to a change to the Virginia public meeting laws that became effective on July 1, 2024.

**Adoption of Agenda**

Chairman Meyers advised that the first order of business was the adoption of the draft agenda for the meeting and noted that everyone should have received a copy of the draft agenda from Ms. Stroble. He then asked for a motion to adopt the agenda. Mr. Bommarito made a motion to adopt the agenda, which was seconded by Dr. LeBeau. The agenda was adopted by unanimous vote of the Subcommittee.

**Adoption of Draft Minutes from the October 12, 2021 Subcommittee Meeting**

Chairman Meyers noted that the draft minutes from the October 12, 2021 meeting of the Subcommittee were previously shared and asked if there were any proposed changes. Being none, he asked for a motion to approve the minutes. Mr. Bommarito made the motion, which was seconded by Dr. LeBeau and approved by unanimous vote of the Subcommittee.

47 **Discussion of Method Validation Summary**

48 In advance of the meeting, the members of the Subcommittee were provided with the method  
49 validation summary documentation for the following method:

- 50 • Addition of Delta-7 and cis-Delta-9 Tetrahydrocannabinol (THC) Isomers to Existing Semi-  
51 Quantitative Gas Chromatography-Flame Ionization Detection/Mass Spectrometry (GC-  
52 FID/MS) Method

53 Dr. Rebecca Wagner, Chemistry Research Section Supervisor, provided an overview of the method  
54 validation summary, noting that it is a full validation expanding the number of THC isomers that can  
55 be evaluated with this semi-quantitative method. The Subcommittee members had no questions or  
56 recommendations. Chairman Meyers commented that the validation was very thorough, and all data  
57 well explained.

58 **Discussion of Method Validation Plan**

59 In advance of the meeting, the members of the Subcommittee were provided the method validation  
60 plan documentation for the following method:

- 61 • Quantitative Analysis of Fentanyl using Gas Chromatography-Flame Ionization  
62 Detection/Mass Spectrometry (GC-FID/MS)

63 Dr. Wagner provided an overview of the validation plan, noting that this was the Section's first  
64 method using hydrogen as the carrier gas. There was a brief discussion of the plan amongst the  
65 Subcommittee members and Dr. Wagner.

66 Director Jackson pointed out that the agenda mistakenly listed this plan as a *Qualitative* Analysis of  
67 Fentanyl, rather than a *Quantitative* Analysis. Chairman Meyers asked for a motion to make the  
68 change to the agenda. Mr. Bommarito made the motion, which was seconded by Dr. LeBeau and  
69 passed unanimously.

70 There was further discussion between Subcommittee members and Dr. Wagner regarding the  
71 validation plan surrounding the question of whether there is a particular recovery that has to be  
72 achieved in order to determine that the method is fit for purpose.

73 With no further comments or questions, Chairman Meyers called for a motion to close both reviews.  
74 Dr. LeBeau made the motion, which was seconded by Mr. Bommarito and passed unanimously.

75 **Public Comment**

76 There was an opportunity for public comments. None were made.

77 **Adjournment**

78 Chairman Meyers asked for a motion to adjourn the meeting. Dr. LeBeau made a motion that the  
79 meeting be adjourned, which was seconded by Mr. Bommarito and passed by unanimous vote. The  
80 meeting was adjourned at 1:29 p.m.